Nicholas B La Thangue

Title: Innovations of Nicholas B La Thangue

Introduction

Nicholas B La Thangue is a prominent inventor based in Glasgow, GB. He has made significant contributions to the field of biotechnology, particularly in the development of peptide antagonists and transcription factors. With a total of five patents to his name, his work has the potential to impact various medical applications.

Latest Patents

One of his latest patents involves peptide antagonists of DP transcription factors. This invention provides a polypeptide consisting essentially of a sequence corresponding to residues 163 to 199 of DP-1, capable of antagonizing the heterodimerization of a DP protein with an E2F protein. Such peptides may be utilized to induce apoptosis in cardiovascular cells, and the peptide can be delivered in a stent to treat or prevent restenosis. Another notable patent is related to two novel transcription factors belonging to the E2F gene family, specifically human and murine E2F-5. These transcription factors can interact with DP-1 and p130, showcasing the innovative nature of his research.

Career Highlights

Nicholas B La Thangue has established himself as a key figure in his field through his innovative research and patent contributions. His work at Prolifix Limited has allowed him to explore and develop groundbreaking technologies that address critical health issues.

Collaborations

He has collaborated with notable colleagues, including Lasantha R Bandara and Susana De La Luna, further enhancing the impact of his research through teamwork and shared expertise.

Conclusion

Nicholas B La Thangue's contributions to biotechnology through his patents and collaborative efforts highlight his role as an influential inventor. His work continues to pave the way for advancements in medical treatments and therapies.